The main purpose of the project is to develop a pre-series batch of ten UV-A medical devices to accelerate the clinical research activities for validating the theranostics paradigm for the treatment of keratoconus.
The realization of the project objectives will allow Regensight to seize the opportunity to accelerate its entry into the market and lay the foundations to become one of the main world players
committed to reducring the social burden of treatment of keratoconus.